Literature DB >> 29633429

Effect of nicotine and alpha-7 nicotinic modulators on visceral pain-induced conditioned place aversion in mice.

D Bagdas1,2, J A Meade1, Y Alkhlaif1, P P Muldoon1, F I Carroll3, M I Damaj1.   

Abstract

BACKGROUND: Preclinical assays of affective and sensorial aspects of nociception play a key role in research on both the neurobiology of pain and the development of novel analgesics. Therefore, we investigated the effects of nicotine and alpha-7 nicotinic acetylcholine receptor (nAChR) modulators in the negative affective and sensory components of visceral pain in mice. METHODS AND
RESULTS: Intraperitoneal acetic acid (AA) administration resulted in a robust stretching behaviour and conditioned place aversion (CPA) in mice. We observed a dose-dependent reduction in AA-induced stretching and CPA by the nonselective nAChRs agonist nicotine. Mecamylamine, a nonselective nAChRs agonist, was able to block its effects; however, hexamethonium, a peripherally restricted nonselective nicotinic antagonist, was able to block nicotine's effect on stretching behaviour but not on CPA. In addition, systemic administration of α7 nAChR full agonists PHA543613 and PNU282987 was failed to block stretching and CPA behaviour induced by AA. However, the α7 nAChR-positive allosteric modulator PNU120596 blocked AA-induced CPA in a dose-dependent manner without reducing stretching behaviours.
CONCLUSIONS: Our data revealed that while nonselective nAChR activation induces antinociceptive properties on the sensorial and affective signs of visceral pain in mice, α7 nAChRS activation has no effect on these responses. In addition, nonselective nAChR activation-induced antinociceptive effect on stretching behaviour was mediated by central and peripheral mechanisms. However, the effect of nonselective nAChR activation on CPA was mediated centrally. Furthermore, our data suggest a pivotal role of allosteric modulation of α7 nAChRS in the negative affective, but not sensory, component of visceral pain. SIGNIFICANCE: The present results suggest that allosteric modulation of α7 nAChR may provide new strategies in affective aspects of nociception.
© 2018 European Pain Federation - EFIC®.

Entities:  

Year:  2018        PMID: 29633429      PMCID: PMC6179949          DOI: 10.1002/ejp.1231

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  57 in total

1.  Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers.

Authors:  Harumi Kitagawa; Toshiharu Takenouchi; Ryotaro Azuma; Keith A Wesnes; William G Kramer; Donald E Clody; Angela L Burnett
Journal:  Neuropsychopharmacology       Date:  2002-07-11       Impact factor: 7.853

2.  The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice.

Authors:  Carrie L Walters; Sharon Brown; Jean-Pierre Changeux; Billy Martin; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2006-01-14       Impact factor: 4.530

3.  Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates.

Authors:  Patrick M Callahan; Elizabeth J Hutchings; Nancy J Kille; James M Chapman; Alvin V Terry
Journal:  Neuropharmacology       Date:  2012-11-17       Impact factor: 5.250

4.  Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation.

Authors:  Guangchen Ji; Hao Sun; Yu Fu; Zhen Li; Miguel Pais-Vieira; Vasco Galhardo; Volker Neugebauer
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

5.  Animal models of pain for drug discovery.

Authors:  Shailen K Joshi; Prisca Honore
Journal:  Expert Opin Drug Discov       Date:  2006-09       Impact factor: 6.098

6.  In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model.

Authors:  K Freitas; S S Negus; F I Carroll; M I Damaj
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

7.  Expression and pharmacological modulation of visceral pain-induced conditioned place aversion in mice.

Authors:  Deniz Bagdas; Pretal P Muldoon; Shakir AlSharari; F Ivy Carroll; S Stevens Negus; M Imad Damaj
Journal:  Neuropharmacology       Date:  2015-11-27       Impact factor: 5.250

8.  Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration.

Authors:  S Pons; L Fattore; G Cossu; S Tolu; E Porcu; J M McIntosh; J P Changeux; U Maskos; W Fratta
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

9.  Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.

Authors:  S Stevens Negus; Ember M Morrissey; Marisa Rosenberg; K Cheng; Kenner C Rice
Journal:  Psychopharmacology (Berl)       Date:  2010-01-26       Impact factor: 4.530

Review 10.  New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs.

Authors:  Deniz Bagdas; Mine S Gurun; Pamela Flood; Roger L Papke; M Imad Damaj
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

View more
  3 in total

Review 1.  Targeting α7 nicotinic acetylcholine receptors for chronic pain.

Authors:  Ya-Qun Zhou; Dai-Qiang Liu; Cheng Liu; Ai-Jun Xu; Yu-Ke Tian; Wei Mei; Xue-Bi Tian
Journal:  Front Mol Neurosci       Date:  2022-09-30       Impact factor: 6.261

Review 2.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

Review 3.  Marine Toxins and Nociception: Potential Therapeutic Use in the Treatment of Visceral Pain Associated with Gastrointestinal Disorders.

Authors:  Andreina Baj; Michela Bistoletti; Annalisa Bosi; Elisabetta Moro; Cristina Giaroni; Francesca Crema
Journal:  Toxins (Basel)       Date:  2019-07-31       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.